Abstract Details

Title MOGAD Atypical Presentations in Pediatric Patients

Topic Multiple Sclerosis

Presentation(s) P13 - Poster Session 13 (8:00 AM-9:00 AM)

Poster/Presentation
Number 12-002

Background Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an inflammatory, demyelinating condition affecting the central nervous system (CNS). Antibodies targeting the MOG protein are expressed on oligodendrocytes and these antibodies have recently been discovered and found to be associated with several demyelinating conditions affecting the optic nerves, brain and spinal cord. MOGAD has a wide spectrum of clinical presentation and can commonly be associated with an Acute Disseminated Encephalomyelitis (ADEM), optic neuritis, and/or transverse myelitis like picture in the pediatric population.

Objective To discuss a series of unique cases of Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in pediatric patients who presented with atypical initial symptoms.

Design/Methods Case Series

Results In this case series, we present 4 pediatric cases of MOG antibody-associated disease with atypical CNS conditions: autoimmune encephalitis, NMOSD, and concern for CNS vasculitis; as well as a case of refractory MOGAD. This series will discuss the presentation, work-up and management of these cases. In these patients, the typical initial findings of ADEM or optic neuritis either were not present or presented later in the disease course.

Conclusions

This series shows the diversity of initial presentation of MOGAD in pediatric patients. Testing for MOG antibody should be considered in pediatric patients with demyelinating neurologic presentations who may lack symptoms commonly associated with MOGAD. Early identification of the MOG antibody can help with effective treatment and management of these patients.

Authors/Disclosures
Victoria A. Adeseye, MD (Texas Children's Hospital) PRESENTER	Dr. Adeseye has nothing to disclose.
	No disclosure on file
Nikita Shukla, MD (BCM)	The institution of Dr. Shukla has received research support from Roche.